Katsiki Niki, Stoian Anca Pantea, Steiropoulos Paschalis, Papanas Nikolaos, Suceveanu Andra I, Mikhailidis Dimitri P
First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, AHEPA University Hospital, 1st Stilponos Kyriakidi, 54621 Thessaloniki, Greece.
Diabetes, Nutrition and Metabolic Diseases Department, "Carol Davila" University of Medicine, 8 Eroii Sanitari, 050474 Bucharest, Romania.
Metabolites. 2020 Nov 15;10(11):465. doi: 10.3390/metabo10110465.
Chronic obstructive pulmonary disease (COPD) is a common disorder with an increasing prevalence, characterised by persistent respiratory symptoms and airflow limitation. Systemic inflammation is involved in the pathogenesis of COPD and can also predispose to metabolic disorders (e.g., metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD)). Such comorbidities can negatively affect COPD outcomes, cardiovascular risk, and quality of life. Apart from NAFLD, abnormal peri-organ or intra-organ fat (APIFat) could be considered as markers for cardiometabolic diseases and even for COPD. The present narrative review considers the associations of COPD with MetS, NAFLD, and other APIFat, including epicardial, perirenal, peripancreatic, and intramuscular adipose tissue. Further research is needed to define these relationships and identify any potential clinical implications.
慢性阻塞性肺疾病(COPD)是一种常见疾病,其患病率不断上升,特征为持续的呼吸道症状和气流受限。全身炎症参与COPD的发病机制,还可能导致代谢紊乱(如代谢综合征(MetS)和非酒精性脂肪性肝病(NAFLD))。这些合并症会对COPD的预后、心血管风险和生活质量产生负面影响。除了NAFLD,器官周围或器官内异常脂肪(APIFat)可被视为心脏代谢疾病甚至COPD的标志物。本叙述性综述探讨了COPD与MetS、NAFLD以及其他APIFat(包括心外膜、肾周、胰周和肌肉内脂肪组织)之间的关联。需要进一步研究来明确这些关系并确定任何潜在的临床意义。